Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie i badanie na badaniach i badanie nawozu in vitro (FIRST)

6 października 2026 zaktualizowane przez: Gameto, Inc.

Randomizowane badanie kontrolne fazy III w celu zbadania bezpieczeństwa i skuteczności nawozu w porównaniu z medyczkowym dojrzewaniem in vitro (IVM)

The goal of this clinical trial is to evaluate the safety and efficacy of using Fertilo for In vitro maturation (IVM) in participants 18-35 years of age. The main question it aims to answer is whether the use of Fertilo is superior to using Medicult IVM for In vitro maturation.

Researchers will compare the number of ongoing pregnancies at 12 weeks gestation for participants in each arm.

  • Arm 1 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Fertilo for 30 hours.
  • Arm 2 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Medicult IVM for 30 hours.

Przegląd badań

Status

Rekrutacyjny

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Szacowany)

500

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

  • Stany Zjednoczone
    • California
      • Clovis, California, Stany Zjednoczone, 93611
        • Rekrutacyjny
        • Women's Specialty & Fertility Center
        • Kontakt:
        • Główny śledczy:
          • Howard Synn, MD
      • Encino, California, Stany Zjednoczone, 91436
    • Florida
      • Clearwater, Florida, Stany Zjednoczone, 33759
        • Rekrutacyjny
        • Florida Fertility Institute
        • Kontakt:
        • Główny śledczy:
          • Mark Sanchez, MD
      • Pembroke Pines, Florida, Stany Zjednoczone, 33026
        • Rekrutacyjny
        • IVF Florida
        • Kontakt:
        • Główny śledczy:
          • Luis Hoyos, MD
    • Maryland
      • Rockville, Maryland, Stany Zjednoczone, 20850
    • New York
      • New York, New York, Stany Zjednoczone, 10019
        • Rekrutacyjny
        • Columbia University Fertility Center
        • Kontakt:
        • Główny śledczy:
          • Eric Forman, MD
    • North Carolina
      • Charlotte, North Carolina, Stany Zjednoczone, 28207
      • Raleigh, North Carolina, Stany Zjednoczone, 27607
    • Texas
      • Addison, Texas, Stany Zjednoczone, 75001
        • Rekrutacyjny
        • Aspire Fertility Dallas
        • Główny śledczy:
          • Christine Mansfield, MD
        • Kontakt:
      • Austin, Texas, Stany Zjednoczone, 78705
        • Rekrutacyjny
        • Aspire Fertility Austin
        • Główny śledczy:
          • Angela Kelley, MD
        • Kontakt:
      • Bedford, Texas, Stany Zjednoczone, 76022
        • Rekrutacyjny
        • Care Fertility
        • Główny śledczy:
          • Kevin Doody, MD
        • Kontakt:
        • Kontakt:
      • Dallas, Texas, Stany Zjednoczone, 75231
        • Rekrutacyjny
        • Dallas Fort Worth Fertility Associates
        • Kontakt:
        • Główny śledczy:
          • Samuel Chantilis, MD
      • San Antonio, Texas, Stany Zjednoczone, 78528
        • Rekrutacyjny
        • Aspire Fertility San Antonio
        • Główny śledczy:
          • Jennifer Knudtson, MD
        • Kontakt:
      • San Antonio, Texas, Stany Zjednoczone, 78249
        • Rekrutacyjny
        • Pozitivf Fertility San Antonio
        • Kontakt:
        • Główny śledczy:
          • Francisco Arredondo, MD
      • Webster, Texas, Stany Zjednoczone, 77598
    • Utah
      • Pleasant Grove, Utah, Stany Zjednoczone, 84062
        • Rekrutacyjny
        • Utah Fertility Center
        • Kontakt:
        • Główny śledczy:
          • Shawn Gurtcheff, MD

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 35 lat (Dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Kobieta

Opis

Inclusion Criteria:

  1. Written informed consent.
  2. Premenopausal, Age 18-35.
  3. Body mass index (BMI) 21-40.
  4. Candidate for IVF according to the ASRM definition (infertile for ≥12 months, require the use of donor sperm, or the inability to achieve a successful pregnancy based on a patient's medical, sexual, and reproductive history, age, physical findings, diagnostic testing, or any combination of those factors).
  5. No contraindications to the use of oral contraceptive pills (OCP) or gonadotropins.
  6. Plan to use embryos for transfer within 2 months of blastocyst cryopreservation.
  7. Anti-mullerian hormone (AMH) ≥ 3 ng/mL within 6 months of Screening/Visit 1 or assessed at the screening visit.
  8. Normal uterine cavity as assessed by hysteroscopy, hysterosalpingography or sonohysterography within 12 months of Screening/Visit 1 or assessed at the screening visit.
  9. Having adequate visualization of both ovaries, without evidence of significant abnormality/pathology or major cyst documented by transvaginal ultrasound within 3 months of screening or assessed during screening period.
  10. No endometriosis of American Fertility Society (AFS) grade 3 or 4 or presence of endometrioma.
  11. Minimum of 1 month without treatment with either clomiphene citrate, GnRH agonist or gonadotropins prior to start of ovarian stimulation.
  12. Have a male partner with semen analysis within the past 12 months prior to randomization considered adequate to proceed with intracytoplasmic sperm injection (ICSI) according to the center's standard practice. If this criterion is not met, the subject can only be entered if donor sperm will be used.

Exclusion Criteria:

  1. History of recurrent pregnancy loss (defined as >2 clinical pregnancies without live birth).
  2. Baseline prolactin levels greater than 30 ng/ml
  3. Male: requirement for retrograde ejaculation procedures or surgical sperm retrievals.
  4. Any clinically relevant pathology that in the judgment of the investigator could impair embryo implantation or pregnancy continuation.
  5. Use of preimplantation genetic testing (PGT) of oocytes, embryos, or transferred blastocysts during participation in the study.
  6. Use of donated oocytes, embryos or blastocysts for this treatment cycle while participating in the study or use of oocytes, embryos, or blastocysts from a previous treatment cycle.
  7. Participation in a concurrent clinical trial or in another investigational drug trial within the past 2 months.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Inny
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Fertilo

Immature cumulus-oocyte complexes (COCs) are oocytes surrounded by cumulus cells that have not yet matured. The COCs are cultured in Fertilo coculture condition then fertilized, grown to the blastocyst stage, vitrified, and later transferred for reproductive purpose.
Biologiczny: Fertilo

Fertilo is an engineered line of ovarian support cells that aid egg maturation.
Aktywny komparator: Medicult IVM®

Immature COCs are cultured in the standard IVM system MediCult IVM® then fertilized, grown to the blastocyst stage, vitrified, and later transferred for reproductive purpose.
Urządzenie: Medicult IVM

MediCult IVM is a system of culture media designed for the in vitro maturation of immature oocytes.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Demonstration of the superiority of Fertilo compared to the currently approved MediCult IVM® for infertility treatment via IVF procedures.
Ramy czasowe: 12 weeks gestation

Cumulative ongoing pregnancy from cycles initiated within 6 months post-randomization. The primary endpoint of ongoing pregnancy is assessed at 12 weeks gestation or later. Cumulative ongoing pregnancy is determined using the cumulative outcome of up to the first two embryo transfers. Subjects with a detectable fetal heartbeat, considered normal and healthy, are considered as having achieved an ongoing pregnancy. "Normal" will be determined as expected for the gestational age ranging from 110 bpm to 180 bpm and measured via ultrasound. Ongoing pregnancy is recorded as either a Yes or No for normal fetal heart rate present for each of the Subject's transfer cycles. Subjects without an ongoing pregnancy assessment are considered as a No unless a later observation indicates otherwise (i.e., a live birth). Cumulative ongoing pregnancy is derived as either a Yes, if at least one of the first two embryo transfers achieves an ongoing pregnancy, or a No otherwise.
12 weeks gestation

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Metaphase II (MII) Formation
Ramy czasowe: 30 hours post-oocyte retrieval

MII formation rate is assessed at 30 hours post-oocyte retrieval. A Metaphase II (MII) oocyte is defined as an oocyte with a first polar body (PB1). The MII formation rate is measured as a Subject's total number of MII oocytes divided by their total number of COCs. The MII formation rate is multiplied by 100 and expressed as a percentage.
30 hours post-oocyte retrieval
Fertilization Rate
Ramy czasowe: 16-18 hours post-ICSI

Fertilization rate is assessed at 16-18 hours post-ICSI. Fertilized embryos displaying 2 pronuclei and 2 polar bodies are considered normally fertilized. Fertilized embryos with no pronuclei are considered not fertilized. Fertilized embryos with one pronuclei are held to determine cleavage, as pronuclei visualization timing may mask the second pronucleus. The fertilization rate is measured as a Subject's total number of fertilized embryos divided by their total number of COCs. The fertilization rate is multiplied by 100 and expressed as a percentage.
16-18 hours post-ICSI
Embryo cleavage rate
Ramy czasowe: Day 3 post-ICSI

Embryo cleavage rate is assessed at day 3 post-ICSI. Embryos with 2 or more cells are considered as cleaved. Fertilized embryos displaying a single cell will be considered not cleaved. The cell cleavage rate is measured as a Subject's total number of embryos considered as cleaved divided by their total number of COCs. The cell cleavage rate is multiplied by 100 and expressed as a percentage.
Day 3 post-ICSI
High quality blastocyst formation rate.
Ramy czasowe: Day 5, 6, and 7 post-ICSI

High quality blastocyst formation rate is assessed at day 5, 6 and 7 post-ICSI. Embryos that have successfully passed the morula stage, as indicated by cavitation, will be designated as blastocysts and will be graded according to the Gardner Scale. Blastocysts having a Gardner Scale score of 3CC or higher are considered as high quality blastocysts. The high quality blastocyst formation rate is measured as a Subject's total number of high quality blastocysts divided by their total number of COCs. The high quality blastocyst formation rate is multiplied by 100 and expressed as a percentage.
Day 5, 6, and 7 post-ICSI
High quality vitrified blastocyst rate.
Ramy czasowe: Day 5, 6, and 7 post-ICSI

High quality vitrified blastocyst rate is assessed at day 5, 6 and 7 post-ICSI. Embryos deemed high quality, as measured by a Gardner score of 3CC of greater, that have been vitrified, a method of rapid cryopreservation for future embryo transfer, will be designated as high quality vitrified blastocysts. The high quality vitrified blastocyst rate is measured as a Subject's total number of high quality blastocysts that are vitrified divided by their total number of COCs. The high quality vitrified blastocyst rate is multiplied by 100 and expressed as a percentage.
Day 5, 6, and 7 post-ICSI
Cumulative biochemical pregnancy.
Ramy czasowe: 10 to 14 days following FET

Cumulative biochemical pregnancy from cycles initiated within 6 months post randomization. Biochemical pregnancy is assessed at 10 to 14 days following FET. Cumulative biochemical pregnancy is determined using the cumulative outcome of up to the first two embryo transfers. Subjects with BHCG value greater than 5 mIU/mL on two separate tests are considered as achieving biochemical pregnancy. Biochemical pregnancy is recorded as either a Yes or No for each of the Subject's transfer cycles. Subjects without a biochemical pregnancy assessment are considered as a No unless a later observation indicates otherwise (i.e., a clinical pregnancy, ongoing pregnancy, or live birth). Cumulative biochemical pregnancy is derived as either a Yes, if at least one of the first two embryo transfers achieves a biochemical pregnancy, or a No otherwise.
10 to 14 days following FET
Cumulative clinical pregnancy.
Ramy czasowe: 4-6 weeks gestation

Cumulative clinical pregnancy from cycles initiated within 6 months post randomization is assessed at 4-6 weeks gestation. Cumulative clinical pregnancy is determined using the cumulative outcome of up to the first two embryo transfers. Subjects with a gestational sac visualized with TVU are considered as having achieved a clinical pregnancy. Clinical pregnancy is recorded as either a Yes or No for each of the Subject's transfer cycles. Subjects without a clinical pregnancy assessment are considered as a No unless a later observation indicates otherwise (i.e., an ongoing pregnancy or live birth). Cumulative clinical pregnancy is derived as either a Yes, if at least one of the first two embryo transfers achieves a clinical pregnancy, or a No otherwise.
4-6 weeks gestation
Cumulative live birth.
Ramy czasowe: Greater than 24 weeks gestation

Cumulative live birth from cycles initiated within 6 months post-randomization. Live birth is confirmed at >24 weeks gestation by the presence of signs of life such as breathing, heartbeat, pulsation of the umbilical cord, or definitive movement of voluntary muscles. Cumulative live birth is determined using the cumulative outcome of up to the first two embryo transfers. Subjects with at least one neonate meeting the definition of live birth are considered as having achieved a live birth. Live birth is recorded as either a Yes or No for each of the Subject's transfer cycles. Subjects without a live birth assessment are considered as a No. Cumulative live birth is derived as either a Yes, if at least one of the first two embryo transfers achieves a live birth, or a No otherwise.
Greater than 24 weeks gestation

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Gameto, Inc.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

17 kwietnia 2025

Zakończenie podstawowe (Szacowany)

1 maja 2027

Ukończenie studiów (Szacowany)

1 stycznia 2028

Daty rejestracji na studia

Pierwszy przesłany

27 lutego 2025

Pierwszy przesłany, który spełnia kryteria kontroli jakości

27 lutego 2025

Pierwszy wysłany (Rzeczywisty)

5 marca 2025

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

7 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

6 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • GAM-01

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Ramy czasowe udostępniania IPD

Beginning 3 months and ending 5 years following article publication.

Kryteria dostępu do udostępniania IPD

Researchers who provide a methodologically sound proposal. Requestord will need to contact clinicaltrials@gametogen.com and sign a data access agreement.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ICF

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj